MAP2K7 and plasma cell myeloma: These data are consistent with the findings from preclinical studies of MEK inhibitors, showing the inhibition of myeloma cell proliferation and the abrogation of paracrine signals for MM cell survival within the bone marrow niche, thus blocking osteoclast differentiation and reducing myeloma-induced angiogenesis [29-32].